Lung cancer is a disease of public health importance world wide due to very low survival rate. The prognosis for advanced lung cancer is further poor with an approximate 13% overall 5-year survival rate. There not enough data from this part of world. Hence, this study was planned to determine survival in Non Small Cell Lung Cancer (NSCLC) in patients who are on carboplatin and paclitaxel combination chemotherapy which is the most affordable and commonly used treatment regimen being used in India.
Newly diagnosed, treatment-naive patients who underwent chemotherapy (carboplatin and paclitaxel combination) for NSCLC during October-2007 to October-2008 were studied prospectively from date of diagnosis. All the patients were strictly followed up till death or till date. Data analysis was done using HPSS 11.5 and survival was evaluated using Kaplan Meier Curve.
70 patients were studied, mean (± Standard Deviation) age was 57.9 (±8.1) years, 63 male and 7 females, 56 (80%) patients were smokers with median (range) smoking-pack-years of 26(0.5 to 87.5). Median (range) Karnofsky Performance Status score was 60 (40 to 90). All the patients were of advanced stage lung cancer (IIIB and IV). Median (range) delay in initial of treatment after confirmation of diagnosis was 16 (1 to 110) days. Mean (Standard Error of Mean) survival was 372 (32) days (95% CI=310–434).Mean survival was no different between the two sexes. Mean survival in smokers was significantly less than non-smokers [330 (95% CI=262.9 to 396.6) compared with 523 (95% CI= 406.2 to 639.5)]. Figure-1 Kaplan Meier Curve shows survival in studied patients.
Active smoking behaviour is independent predictor of survival in patients with advanced stage NSCLC. Overall survival in our patients was lower than studies published from Western Countries which could attributed to chemotherapy being used specially considering the affordability and also to starting treatment at advanced stage.
Smoking cessation should be first step as a primary prevention and to decrease mortality in lung cancer.
Subhash Chandra, No Financial Disclosure Information; No Product/Research Disclosure Information